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Abstract
Aims Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis.
We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart
failure with preserved ejection fraction (HFpEF).
Methods and results This study was a post-hoc analysis of the MUSCAT-HF trial (UMIN000018395), a multicentre,
prospective, open-label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily,
n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in
patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from
baseline to Weeks 4, 12, and 24, using a mixed-effects model for repeated measures. We also estimated the association
between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced
ePV as compared to voglibose at Week 4 {adjusted mean group-difference 6.43% [95% confidence interval (CI): 9.11 to
3.74]}, at Week 12 [8.73% (95%CI: 11.40 to 6.05)], and at Week 24 [11.02% (95%CI: 13.71 to 8.33)]. The effect
of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV
at Week 12 was significantly associated with log-transformed BNP (r = 0.197, P = 0.015) and left atrial volume index
(r = 0.283, P = 0.019).
Conclusions Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with
voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes
and HFpEF.
Keywords Estimated plasma volume; Heart failure with preserved ejection fraction; Luseogliflozin; Sodium glucose co-transporter 2
inhibitors; Voglibose
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Introduction
There has been a paucity of evidence for treatments that can
improve the prognosis of patients with heart failure with
preserved ejection fraction (HFpEF), although various
medications have resulted in improved prognosis of patients
with heart failure with reduced ejection fraction (HFrEF).1–7
Some clinical trials have evaluated the effectiveness of medi-
cal treatments for HFpEF but have not established their
benefits.8–11
Sodium glucose co-transporter 2 (SGLT2) inhibitors are an-
tidiabetic drugs that promote urinary glucose excretion.
SGLT2 inhibitors seem to have some benefits beyond their
glucose-lowering effects, promoting natriuresis and osmotic
diuresis based on glycosuria.12 Previous studies have shown
that SGLT2 inhibitors reduce the rehospitalization of patients
with type 2 diabetes due to heart failure and renal function
deterioration.13,14 In addition, recent studies reported that
SGLT2 inhibitors improved the prognosis of patients with
HFrEF, regardless of the presence or absence of type 2 diabe-
tes mellitus (T2DM).15 Moreover, some previous studies have
shown that SGLT2 inhibitors reduce hospitalization for heart
failure (HF) in patients with HFpEF. 16,17 Recently, SGLT2 in-
hibitors have been reported to reduce estimated plasma vol-
ume (ePV).18–21 Although these results suggest that SGLT2
inhibitors may be effective in reducing intravascular volume,
which may improve heart failure prognosis, there is little
evidence of the efficacy of SGLT2 inhibitors on intravascular
volume in patients with HFpEF.
In the Management of Diabetic Patients with Chronic Heart
Failure and Preserved Left Ventricular Ejection Fraction
(MUSCAT-HF) trial, brain natriuretic peptide (BNP) concentra-
tions decreased after initiation of either luseogliflozin, an
SGLT2 inhibitor, or voglibose, an alpha-glucosidase inhibitor,
at Week 12.22 However, the difference in change in BNP levels
was not statistically significant [percent change, 9.0% vs.
1.9%; ratio of change with luseogliflozin vs. voglibose,
0.93; 95% confidence interval (CI), 0.78–1.10; P = 0.26].
In this post-hoc analysis of the MUSCAT-HF trial, we com-
pared the impact of luseogliflozin and of voglibose on the re-
duction of ePV and evaluated the correlation of change in
ePV with BNP level and other clinical parameters in patients
with T2DM and HFpEF.
Materials and methods
Study design and participants
This was a post-hoc analysis of the MUSCAT-HF trial, a multi-
centre, prospective, open-label, randomized controlled trial
to assess the effect of luseogliflozin compared with voglibose
on left ventricular load in patients with T2DM and HFpEF.22
Details of the study design and results have been published
previously.22,23 The original study examined the effects of a
12 week treatment of patients with T2DM and HFpEF with
luseogliflozin (2.5 mg) once daily vs. voglibose (0.2 mg) three
times daily in 165 patients aged ≥ 20 years who required
additional treatment for T2DM, despite ongoing treatment.
HFpEF was defined as a left ventricular ejection fraction
(EF) ≥ 45%, BNP concentrations ≥ 35 pg/mL, and any
symptoms. Patients treated with alpha-glucosidase inhibitors,
SGLT2 inhibitors, glinides, or high-dose sulfonylurea;
renal insufficiency [estimated glomerular filtration rate
(eGFR) < 30 mL/min/1.73 m2); a history of severe
ketoacidosis or diabetic coma within 6 months prior to partic-
ipation; and poorly controlled T2DM [haemoglobin A1c
(HgbA1c) > 9.0%) were excluded. Patients were randomly
assigned to the two drug arms, and post-randomization
follow-up visits were scheduled at Weeks 4, 12, and 24. The
primary outcome of the original study was the change in
the ratio of BNP concentrations from baseline to 12 weeks
of treatment. The investigation conformed to the principles
outlined in the Declaration of Helsinki. The study was
approved by the Ethics Committee of Okayama University
Graduate School of Medicine, Density and Pharmaceutical
Sciences. All patients enrolled in this study provided written
informed consent. The trial was registered in the University
Hospital Medical Information Network Clinical Trial Registry
(UMIN-CTR, UMIN000018395).
Outcomes
The primary outcome of this post-hoc analysis was the
between-group differences in the percentage change in ePV
from baseline to 12 weeks. Additionally, in the luseogliflozin
group, the association between changes in ePV and changes
in other clinical parameters was evaluated.
Estimated plasma volume
The ePV at baseline was measured using the Hakim
formula as follows: (1  haematocrit) × (1530 + [41 × body
weight (kg)]) in male patients and (1  haematocrit) ×
(864 + [47.9 × body weight (kg)]) in female patients.24 The
percentage change in ePV at Weeks 4, 12, and 24 from
baseline was calculated using the Strauss formula as
follows: 100 × [haemoglobin (at baseline)/haemoglobin
(at visit)] × [1  haematocrit (at visit)]/[1  haematocrit
(at baseline)]  100.25 We measured BNP levels in a central
laboratory (SRL, Inc. Hachioji, Tokyo, Japan). Haemoglobin,
haematocrit, aspartate aminotransferase, alanine amino-
transferase, blood urea nitrogen, serum creatinine, eGFR,
and HgbA1c were also evaluated. These parameters were
measured in each institution.
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Statistical analysis
Categorical variables are presented as numbers (%) and were
compared using the χ2 test. Normally distributed continuous
variables are presented as mean ± standard deviation and
were compared using Student’s t-test. Continuous variables
that were not normally distributed are presented as medians
with interquartile ranges and were compared using the
Mann–Whitney U-test. The normality of the data distribution
was evaluated using the Shapiro–Wilk test. We estimated
group differences in the mean percentage change in ePV
from baseline to Weeks 4, 12, and 24, and the interaction be-
tween follow-up periods and groups using mixed-effect linear
regression models. The effects of luseogliflozin vs. voglibose
on ePV after 12 weeks were assessed in several subgroups
defined by sex, body weight, prior atherosclerotic cardiovas-
cular disease, and factors used at randomization: age
(<65 years, ≥65 years), sex, baseline HgbA1c values
(<8.0%, ≥8.0%), baseline BNP concentrations (<100 pg/mL,
≥100 pg/mL), baseline renal function (eGFR ≥ 60 mL/min/
1.73 m2, <60 mL/min/1.73 m2), use of thiazolidine (yes or
no), presence or absence of atrial fibrillation or flutter at
baseline, presence or absence of prior atherosclerotic
cardiovascular disease, use of β-blocker (yes or no), use of an-
giotensin-converting enzyme inhibitor or angiotensin II recep-
tor blocker (yes or no), and use of diuretic (yes or no). We
assessed the associations between changes from baseline to
Week 12 in the ePV, BNP levels, and other parameters using
Pearson’s correlation analyses and linear regression models.
Continuous variables that were not normally distributed
underwent natural logarithmic transformation prior to use
in regression analysis. Statistical significance was defined as
P < 0.05. These analyses were performed using SPSS statisti-
cal software (Version 25; IBM Corp., Armonk, NY, USA).
Patient and public involvement




This post-hoc analysis included 165 patients with T2DM and
HFpEF from 16 hospitals and clinics. The baseline characteris-
tics of the patients are shown in Table 1. The baseline vari-
ables, including laboratory data and echocardiographic
parameters, were similar between the luseogliflozin and
voglibose groups, except for the patients’ age, aspartate
aminotransferase, and alanine aminotransferase.
Comparison of the estimated plasma volume
between groups
In the mixed-effect models for repeated measures, there was
a statistically significant interaction between the effect of the
study drugs and the follow-up periods (P < 0.001 for interac-
tion) (Figure 1). ePV was reduced more by luseogliflozin than
by voglibose from baseline to Week 4 [adjusted mean group-
difference, 6.43% (95%CI: 9.11 to 3.74%)], Week 12
[8.73% (95%CI: 11.40 to 6.05%)], and Week 24
[11.02% (95%CI: 13.71 to 8.33%)].
The effects of luseogliflozin vs. voglibose on ePV observed
in the overall population at Week 12 were similar to those in
the various patient subgroups (Figure 2). Specifically, com-
pared with voglibose, luseogliflozin reduced ePV by
7.978% (95%CI: 11.81 to 4.14%) in patients with
BNP < 100 pg/mL and by 10.94% (95%CI: 18.64 to
3.24%) in patients not using diuretics (P value for treatment
by subgroup interaction = 0.45). Among patients with an
eGFR < 60 mL/min/1.73 m2, luseogliflozin compared with
voglibose reduced ePV by 10.83% (95%CI: 15.28 to
6.37%). In patients with eGFR ≥ 60 mL/min/1.73 m2, ePV
was reduced by 6.01% (95%CI: 11.17 to 4.19%), as
compared with voglibose (P value for treatment by subgroup
interaction = 0.166). Among patients with a body
weight < 60 kg, luseogliflozin compared with voglibose
reduced ePV by 6.17% (95%CI: 11.78 to 0.56%). In
patients with body weight ≥ 60 kg, ePV was reduced by
10.45% (95%CI: 14.85 to 6.04%), as compared with
voglibose (P value for treatment by subgroup interac-
tion = 0.23). Luseogliflozin decreased ePV by 8.78% in
patients with a history of atherosclerotic cardiovascular
disease, as well as in patients without atherosclerotic
cardiovascular disease (P value for treatment by subgroup in-
teraction = 0.54). All P values for interaction, except for
β-blocker use, were > 0.05.
Association between the estimated plasma
volume and clinical parameters
In the Pearson correlation analyses, the change from baseline
to Week 12 in log-transformed BNP concentration was
positively correlated with the percentage change in ePV
(Figure 3). There were statistically significant correlations be-
tween changes in ePV at Week 12 and concurrent changes in
haemoglobin levels and the left atrial volume index (Table 2).
Discussion
In this post-hoc analysis of the MUSCAT-HF trial, the impact
of luseogliflozin on the change in ePV at Weeks 4, 12, and
Luseogliflozin and estimated plasma volume in HFpEF 3
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13683
Table 1 Baseline clinical characteristics of this study
Variables Luseogliflozin (n = 83) Voglibose (n = 82) P value
Age (years) 71.7 ± 7.7 74.6 ± 7.7 0.017
Male 55 (66) 48 (59) 0.31
Body mass index (kg/m2)
Systolic blood pressure (mmHg) 131 ± 17 128 ± 14 0.168
Diastolic blood pressure (mmHg) 71 ± 11 71 ± 10 0.52
Heart rate (beats per minute) 69 ± 13 70 ± 12 0.53
Hypertension 72 (89) 64 (79) 0.087
Dyslipidaemia 65 (80) 61 (75) 0.45
Prior ASCVD 48 (59) 50 (62) 0.75
Atrial fibrillation or flutter 18 (22) 15 (18) 0.59
Medications on admission
β-blocker 51 (61) 47 (57) 0.39
ACEI/ARB 51 (61) 47 (57) 0.59
MRA 19 (23) 20 (24) 0.97
Loop diuretic 19 (23) 19 (23) 0.97
Thiazide 5 (6.0) 5 (6.1) 0.98
Antidiabetic medication 53 (65) 50 (61) 0.74
Laboratory data
HgbA1c (%) 7.0 ± 0.7 6.9 ± 0.8 0.52
Haemoglobin (g/dL) 13.5 ± 1.6 13.1 ± 1.6 0.114
Haematocrit (%) 41.4 ± 4.8 40.4 ± 4.2 0.159
AST (IU/L) 27.2 ± 16.8 23.2 ± 7.0 0.048
ALT (IU/L) 25.3 ± 18.5 19.4 ± 9.8 0.010
Blood urea nitrogen (mEq/L) 17.7 ± 5.5 19.1 ± 6.0 0.119
Serum creatinine (mg/dL) 0.94 ± 0.30 0.96 ± 0.29 0.70
Estimated GFR (mL/min/1.73 m2) 60.6 ± 19.4 56.8 ± 16.5 0.185
BNP (pg/mL) 63.7 (46.8–115.8) 75.1 (42.4–120) 0.87
Echocardiographic data
LVEF (%) 57 ± 9.4 58 ± 9.4 0.41
E/A 0.77 ± 0.21 0.85 ± 0.29 0.094
e’ (cm/s) 5.4 ± 1.5 5.6 ± 1.8 0.66
E/e’ 13.0 ± 4.5 13.3 ± 5.6 0.67
LAD (mm) 42.0 ± 7.4 42.5 ± 7.9 0.69
LAVI (mL/m2) 37.9 ± 16.3 38.4 ± 13.5 0.84
LVMI (g/m2) 93.0 ± 23.2 91.3 ± 27.5 0.71
ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker, ASCVD, atheroscle-
rotic cardiovascular disease; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; E/A; early/atrial mitral inflow velocity,
E/e’, Early diastolic filling velocity/early diastolic velocity of the mitral annulus; estimated GFR, estimated glomerular filtration rate;
HgbA1c, haemoglobin A1c; LAD; Left atrial dimension, LAVI; left atrial volume index; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist.
Data are presented as the number (%), mean ± standard deviation, or median (25th–75th percentile).
Figure 1 Effect of luseogliflozin relative to voglibose on ePV from baseline through Week 24. Adjusted mean changes from baseline in estimated
plasma volume (%) and 95% confidence interval are displayed. eGD, estimated group difference; ePV, estimated plasma volume.
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24 from baseline was superior to that of voglibose in patients
with T2DM and HFpEF. Changes in ePV were significantly as-
sociated with changes in BNP and left atrial volume index. To
the best of our knowledge, no previous study had
demonstrated that SGLT2 inhibitors can reduce fluid volume
in patients with T2DM and HFpEF.
Figure 2 Changes from baseline in ePV (%) at Week 12 of treatment with luseogliflozin relative to treatment with voglibose in various subgroups. ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BNP, B-type natriuretic
peptide; eGFR, estimated glomerular filtration rate; ePV, estimated plasma volume; HgbA1c, hemoglobinA1c.
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Efficacy of sodium glucose co-transporter 2
inhibitors for reduction in the estimated plasma
volume
Sodium glucose co-transporter 2 inhibitors have some
favourable effects on heart failure beyond their
glucose-lowering effects.12 Previous studies have reported
that SGLT2 inhibitors reduced both the plasma volume
measured by 125I-labelled human serum albumin and ePV
by using laboratory data in patients with T2DM.18,19 Other
studies have also reported that SGLT2 inhibitors reduced
the ePV in patients with T2DM complicated by cardiovascu-
lar diseases or HFrEF.20,21 In addition, SGLT2 inhibitors
reduced pulmonary arterial pressure in patients with heart
failure.26 These results support that SGLT2 inhibitors can re-
duce intracellular volume by diuretic effects related to both
glycosuria and natriuresis, consistent with the results of this
study.
Impact of sodium glucose co-transporter 2
inhibitors on heart failure with preserved ejection
fraction
It has been reported that SGLT2 inhibitors decreased wors-
ening heart failure in patients with HFrEF, regardless of
the presence or absence of diabetes mellitus in a random-
ized trial.15 The present study showed that SGLT inhibitors
have a favourable effect on ePV reduction in patients with
HFpEF. ePV has been reported to be associated with a risk
of worse prognosis in patients with heart failure.27,28
Although the benefit of SGLT2 inhibitors in patients with
HFpEF is not yet established, our results showed the possi-
bility that SGLT2 inhibitors could contribute to improving
clinical outcomes in patients with HFpEF by reducing plasma
volume.
Relationship between estimated plasma volume
and cardiac preloads
In the initial investigation of the MUSCAT-HF study, the pri-
mary finding was that the SGLT2 inhibitor, luseogliflozin, and
the alpha-glucosidase inhibitor did not differ significantly in
reducing BNP concentrations after 12 weeks. In contrast,
this post-hoc analysis showed a significant reduction in
ePV by luseogliflozin, as compared with voglibose, and that
the change in ePV was negatively associated with
haemoglobin and positively associated with changes in BNP
and the left atrial volume index. These results suggest that
SGLT inhibitors may reduce intravascular volume and cardiac
preload.
Some studies have shown that the level of natriuretic
peptides in patients with HFpEF was significantly lower than
that in patients with HFrEF, although an increase in
natriuretic peptides was associated with a worse clinical
outcome in patients with HFpEF.29,30 Additionally, when
heart failure is due to a cause upstream from the left ven-
tricle, pericardial abnormalities, or right-sided heart failure
alone, natriuretic peptide concentrations may be initially
low, despite severe symptoms, because of the absence of
a significant increase in LV wall stress.31 Changes in BNP
may sometimes underestimate the evaluation of the change
in intravascular volume in patients with HFpEF because
HFpEF has various aetiologies. In this situation, measure-
ment of the change in ePV in addition to that in BNP may
Figure 3 Correlation between changes in ePV and BNP concentration.
The mean regression line and 95% confidence intervals are displayed.
BNP, B-type natriuretic peptide; ePV, estimated plasma volume.
Table 2 Pearson correlations between percentage change from
baseline at 12 weeks in e PV and various clinical parameters
r P value
Body weight 0.026 0.579
Systolic blood pressure 0.055 0.509
Diastolic blood pressure 0.045 0.583










ALT, alanine aminotransferase; AST, aspartate aminotransferase; E/
e’, early diastolic filling velocity/early diastolic velocity of the mitral
annulus; estimated GFR, estimated glomerular filtration rate;
HgbA1c, haemoglobin A1c; LAD; left atrial dimension; LAVI; left
atrial volume index; LVEF, left ventricular ejection fraction.
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add sensitive and valuable information about cardiac pre-
load in patients with HFpEF.
Limitations
This study has several limitations. First, this was a post-hoc
analysis of a previous study’s results, which included a rela-
tively small number of patients, and had a short follow-up du-
ration. Second, this study targeted the change in ePV from
baseline after a period of treatment, but there was no actual
measurement of plasma volume, such as by dilution methods
using radioisotopes. Actual plasma volume and ePV may dif-
fer, because ePV is calculated from laboratory data, which
may be influenced by other factors, such as plasma volume
and erythropoietic parameters, which may also be influenced
by SGLT2 inhibitors.32 Third, some patients with mild heart
failure were included in this study. In this study, patients with
a left ventricular EF of ≥45% were enrolled because this study
enrolment had started before the latest definition of HFpEF in
the ESC Heart Failure Guidelines was changed in 2016.33,34 In
the 2016 ESC Heart Failure Guidelines, heart failure with a
left ventricular EF ranging from 40% to 49% were defined
as HF with midrange EF. The effect of luseogliflozin on ePV
in patients with HFpEF might thus not have been accurately
estimated.
Conclusions
In conclusion, ePV in patients with T2DM and HFpEF was
significantly reduced by luseogliflozin compared with
voglibose. SGLT2 inhibitors may therefore be effective in
reducing intravascular volume and cardiac preload in these
patients.
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